RFpeptides creates macrocyclic peptides designed to bind to a specified target, and it doesn’t need to build off an existing peptide structure. Cyrus Harmon, CEO of Vilya, previously told C&EN that these rings are stabler than linear peptides, which are more “floppy” and prone to getting degraded in the body. They could be a midpoint between large biologics, which can bind to a large surface but are too big to be orally bioavailable, and small molecules, which can be ingested but are too small to bind to large surface areas.
Source link
